I read this: “In past releases, we have discu
Post# of 72436
“In past releases, we have discussed disease stabilization and reduction of cancerous lesions in some patients treated with Kevetrin,” said Leo Ehrlich, Chief Executive Officer at Cellceutix. “Now, this new p21 data only reinforces our high expectations for and confidence in Kevetrin, specifically, its potential to treat patients across a broad spectrum of cancer types and even those in late stages with refractory tumors. It is exciting to see our early clinical work in the lab translating to the bedside.”
And I hear "Rosen et all shorts, f' you and your frivolous lawsuit! again!"
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)